At eyeforpharma Barcelona 2019, we will work together to find combined solutions. For this reason, we are bringing together 1300+ decision makers across 6 functions; sales/commercial, marketing/digital, patients, medical, market access and RWE.


Medicine is just the beginning

    • Keynotes
    • Keynotes
The new battlegrounds are not where you expect
  • Why manufacturing and supply chain will be the key differentiator as direct-to-patient supply and admin are the success factors for personalised, biological and specialised medicines
  • Prevention is better than cure: why prophylactic treatments, gene and cell therapies and genomics are priority areas for investment today
    • Keynotes
The Authenticity Factor: how CMOs can pioneer rapid-reaction strategy based on continuous data input
  • Hear the argument for re-centralisation of medical teams in order to create a core of medical expertise
  • Determine to what degree medical and commercial must align – and how to empower them with high-grade datasets
    • Keynotes
Regulation Revolution: how the FDA and EMA are enabling a new era of innovation
  • How patients are becoming the driver of regulatory evolution through incorporating their experience into our benefit-risk assessments.
  • Understand the imminent and significant changes that regulators and payers are devising
    • Keynotes
Let the health entrepreneurs show you how
  • Witness elevator pitches from 6 hand-selected healthcare startups who promise to disrupt pharma – and who could be your next partner
  • Understand the true risk, ambition and what is possible with minimal resources
    • Keynotes
Your agility ability: why adopting more iterative and experimental innovation techniques need a new type of learning culture
  • Why your revenue-focussed objectives will fail in an entrepreneurial environment
  • Ways you can create faster, more experimental innovation without sacrificing safety and reliability
    • Keynotes
Exceed the expectations of increasing consumerization
  • Where we need to move from B2B to B2C and what the finest in FMCG and Financial Services are doing to remodel
  • Move patients from ‘empowered’ to ‘being in charge’ by investing in literacy and enabling them as adjudicators within the access equation.
    • Keynotes
How can we create joint-venture patient initiatives and prevent patient confusion?
  • Why it makes long-term commercial sense to avoid the short-term land grab for your own app or PSP
  • See how new projects have aligned the drivers and incentives between difference companies to enable true partnership to occur
    • Keynotes
We fight for the patient – and the patient fights for us
  • How the smartest companies are able to go beyond empowerment, beyond advocacy and work with patients for sustained access in a virtuous circle
  • Why your goal must be to have the most comprehensive patient insights if you are ever going to gain trusted partner status
    • Keynotes
Prevention is better than cure: how the future of pharma depends on today’s investment in regenerative medicine, cell therapies and genomics
  • How the biological mechanisms can be enhanced and repaired through cost-effective methods for the harvesting, expansion, manipulation and purification of the body’s cells.

Access innovation

    • Market Access
    • Market Access
Panel: Drive market access innovation in a risk averse environment
  • Explore the next steps in creating an environment capable of successfully enacting more outcomes-based agreements
  • Strengthen stakeholder alignment with understanding of the groundwork capabilities needed for data needs
    • Market Access
Pricing innovation in the face of CAR-T and gene therapy
  • Explore how to implement appropriate outcomes-based pricing models to match treatment innovation
  • Understand the new needs of payers given the increasing levels of complexity in timelines and outcomes
    • Market Access
Panel: How to work more openly with HTAs to improve patient care and match medical innovation
  • Discuss the changing needs for value assessment as levels of effectiveness increase
  • How to foster more transparent partnership with government bodies
    • Market Access
Understand the future of early access to support your long-term commercial performance
  • Determine the appropriate criteria to temper your investment in early access schemes
    • Market Access
Hone you value proposition: work with clinical teams to ensure payer needs are built in early into the development paradigm
  • Accelerate development timelines while safeguarding Market Access priorities through close collaboration with R&D colleagues

Redefine Medical’s Value

    • Medical Affairs
    • Medical Affairs
Panel: Medical as leader: discuss how a centralised medical function can improve dynamics with HCPs
  • See whether a concentrated medical HQ team can equip field teams with the skills and capabilities for more effective interactions
  • Discuss the strategic considerations in maintaining a balance of global and regional approaches
    • Medical Affairs
The evolution of Medical Affairs role in the Medicines Development Process
  • Make development patient-centric and value-oriented with a more strategic approach using Medical leadership
  • Understand the structural and capability requires for involvement in the complete life cycle from idea generation on
    • Medical Affairs
Beyond education: become a source of inspiration for HCPs
  • Give HCPs revealing insights about patient populations and enable them to provide real service to patients
    • Medical Affairs
Understand the growing role of Medical Governance in maintaining ethics and compliance in an evolving European regulatory landscape
  • Explore the competency requirements of a modern Medical Affairs function in meeting increasing regulatory requirements
  • Discuss the shifting balance of what constitutes medical information vs commercial activity/material

Catalyse trust in RWE

    • Medical Affairs
    • Data & RWE
    • Market Access
    • Medical Affairs
    • Data & RWE
    • Market Access
Stakeholder Panel: Understand the acceptability of RWE across global regulatory decision-making
  • Explore the evolving role of RWE in the evidence lifecycle, quality expectations and the possibility of regulatory grade RWE
  • Discuss the impact of regulatory policies, such as 21st Century Cures Act, on the global adoption of RWD into R&D and Access framework
    • Medical Affairs
    • Data & RWE
Drive the adoption of RWE
  • Explore key driving forces preventing increased adoption of RWE from a force field perspective
  • Discuss approaches to further build a robust European healthcare data-scape
    • Data & RWE
Federated & harmonised real world research in Europe – 2020 and beyond
  • Discuss key challenges and objectives from key European projects (EMIF & EHDEN) in creating a sustainable harmonised EU data ecosystem
  • Explore current and predicted impact IMI European Health Data Network (EHDEN) now underway

Change the nature of the conversation

    • Digital
    • Commercial
    • Patients
    • Medical Affairs
    • Digital
    • Commercial
    • Patients
    • Medical Affairs
Smarter and more personalised content as the driver of authenticity and authority
  • Co-create content in partnership with customers and find ways to make it more specific
    • Digital
    • Commercial
    • Patients
    • Medical Affairs
Measure yourself against the hardest metrics, including loyalty and advocacy
  • Give HCPs revealing insights about patient populations and enable them to provide real service to patient
    • Digital
    • Commercial
    • Patients
    • Medical Affairs
Panel: Be the go-to source: how your company can become the ultimate guide for customers and patients
  • Can a pharma company become a credible hub for medical and product knowledge?
  • How advances in data capture and analysis can be harnessed to bolster relationships with key stakeholders

Commerical Model Innovation

    • Digital
    • Commercial
    • Patients
    • Digital
    • Commercial
    • Patients
An end-to-end view to your customer suite
  • Adopt a multi-customer model: Physicians, Payers, Policy Makers and Patients. Integrated multi-customer strategies are the way forward.
    • Commercial
Improve personalisation with a 360-degree view of your customer
  • Gain complete visibility of all customer interactions and tailor accordingly
    • Commercial
It's not the size that matters; it's what you do with it
  • Create a rapid-reaction, data-driven sales force which delivers maximum impact with minimal resources
    • Commercial
    • Patients
Panel: Enable your sales force to find traction by aligning with the patient journey
  • How successful reps will combine performance techniques with patient understanding

Create your data symphony

    • Digital
    • Medical Affairs
    • Data & RWE
    • Market Access
    • Medical Affairs
    • Data & RWE
Advance data generation by unlocking the value of academic collaboration
  • Ensure full transparency and compliance to maintain ethics and enhance pharma’s external image
  • Understand the full potential of using academic partners in comparison to traditional CROs
    • Digital
    • Data & RWE
Machine learning and emerging analytical approaches for Regulatory and Safety RWE
  • Lessons learnt in building internal capacity to accept new technology through training and partnerships
  • How to take advantage of new capabilities to combine, use and extract data while staying compliant and ensuring appropriate impact"
    • Medical Affairs
    • Data & RWE
    • Market Access
Hone your RWE generation strategy in Specialty and Rare Diseases
  • Use RWE to define clinical trial endpoints and meet Market Access goals in rare diseases
  • Understand the multiple channels and high quality data sources available and usable

Digital for a new age

    • Digital
    • Commercial
    • Patients
    • Medical Affairs
    • Digital
    • Medical Affairs
LEO Pharma – Growth Hacking their way to the top
  • Hear how LEO Pharma is hacking their way into better HCP engagement, the results and challenges
  • Understand not only the challenges of building the function and the business case for digital marketing
    • Commercial
Determine which analytical and data resources will enable the evolution of your commercial department
  • Streamline commercial activities by selecting and driving the right kind of input data
    • Digital
    • Commercial
    • Patients
Understand how the latest in marketing automation and CRM tech can provide a new communication paradigm
  • How automation of key marketing processes can lift your ability to create bespoke interactions
    • Digital
    • Commercial
Panel: The digitally mature sales function: how you can transform sales reps into catalysts
  • How real digital transformation will be dependent on capabilities of your customer-facing teams

Enhance Medical Interactions with Digital Excellence

    • Digital
    • Medical Affairs
    • Digital
    • Medical Affairs
Use digital as a driver for Medical authenticity and authority
  • Co-create smarter content in partnership with customers and find ways to make it more specific
    • Digital
    • Medical Affairs
The next-generation digital congress experience
  • Amplify the value of your congress campaigns with innovative digital content and communications
  • Use relevant, real-time content to engage with your key customers and stakeholders to improve their congress experience

Genuine Patient Centricty

    • Digital
    • Commercial
    • Patients
    • Medical Affairs
    • Market Access
    • Digital
    • Patients
    • Medical Affairs
    • Market Access
Start with the service to go beyond just 'beyond the pill'
  • Understand how true value can be translated from the patient rather than from the medicine or treatment regimen
    • Digital
    • Commercial
    • Patients
AbbVie case study: Crush Your FOMO – empowering a nation to take control of its health
  • Hear how AbbVie is collaborating with experts from outside the health industry in a bold preventative health move. By putting open-data at the forefront, AbbVie will explore the value of leveraging real-life, data-driven insights to further understand complex human behaviour, in order to ultimately help build a more sustainable NHS.
    • Commercial
    • Patients
    • Medical Affairs
Convince skeptics and prove the commercial value of a patient-centric approach
  • Obtain senior-level support for patient initiatives by linking efforts to outcomes
    • Commercial
    • Patients
    • Market Access
You can’t stand still- innovate into new areas of helping patients
  • Learn how Takeda Austria is taking steps to innovate STEM cell therapy and deliver much needed medicines to patients
  • Understand the implications needed to work together to deliver this 48-hour treatment and how Takeda is over coming these barriers
    • Patients
Panel: From competitors to collaborators - form alliances in the interest of the patient
  • Stop creating your own platforms - co-create the one platform that patients admire

Increase & Demonstrate Field Team Effectiveness

    • Commercial
    • Medical Affairs
    • Commercial
    • Medical Affairs
Field Force Effectiveness Taskforce
  • Explore the evolution of pharma’s medical and commercial field force in a fast-changing external environment
  • In an hour-long interactive session hosted by field force leaders understand emerging capability requirements, measure effectiveness and ensure successful interactions
    • Commercial
    • Medical Affairs
Panel: The rep of tomorrow, today
  • Fast-track a new paradigm for your sales reps and MSLs
  • Define the balance of responsibilities and objectives throughout your whole field team

Medicine is just the beginning

    • Keynotes
    • Keynotes
Partner your way to a real solution
  • What’s your partnership & acquisition strategy? How to identify the organisations that will take your offerings to a completely different level

Open your eyes

    • Data & RWE
    • The ‘Open your Eyes’ Stage
    • Data & RWE
    • The ‘Open your Eyes’ Stage
Genomics and Blockchain: Decentralized genomic big data storage, sharing and analysis
  • Describe how blockchain technology can enable genomic data creation, ensure its security, and allow for its sharing
  • Discuss the future state of genomic research, genomic data security, genomic data standardization and data sharing between individuals and companies as whole genome sequencing costs continue to decrease.
    • Data & RWE
    • The ‘Open your Eyes’ Stage
The Digitome: The first digital representation of health and disease
  • Understand the Human Digitome Project: long-term vision for the platform, including opening it up so that anyone can proactively use it themselves, so that researchers will understand more about how diseases work, and how to cure them.
  • How AI is being used to look for patterns in the ways patients contract diseases and react to medication, to give doctors more information about people’s health
    • The ‘Open your Eyes’ Stage
How single-cell transcriptomics will redefine human diseases and unearth novel therapeutic avenues
  • Everything you need to know about The Human Cell Atlas, an ambitious project, funded by the Chan-Zuckerberg Institute and others, to map every cell in the human body and how this could impact how drugs are developed
  • Learn how the single revolution is rewriting our understanding of a human disease ranging from cancer to inflammatory conditions
    • The ‘Open your Eyes’ Stage
The first biopharma company to be born in the cloud
  • Understand how Moderna Therapeutics has evolved as a truly digital biopharma organization and what this means for advancing drug candidates to clinical studies; increasing the agility of its research, development, and manufacturing processes; and achieveing results—such as personalized cancer vaccines—that would have been impossible even a few years ago.
  • Lessons learnt from their journey and their vision for the future of the company and what this means for the future pharma business model
    • The ‘Open your Eyes’ Stage
Training our immune system to prevent and cure chronic diseases.
  • Understand that the prevention and management of chronic diseases should focus not only on symptomatic patients but on individuals that do not yet have symptoms.
  • Discuss how this disease-prevention strategy profoundly impacts clinical development, marketing and distribution of products, and new payor models.

Patient experience for patient centricuty

    • Commercial
    • Patients
    • Market Access
    • Commercial
    • Patients
Real advocacy - how to become your patient organisation's number one partner
  • Innovate at the cutting edge of patient communication to generate fans, not just advocates
    • Commercial
    • Patients
How Takeda has implemented the patient comes first approach- and the benefits received
  • Ways your organisation can gain maximum patient insights for multiple applications without losing efficiency
  • Ways to deep understanding of patient perspectives and leveraging insights for multiple applications without losing focus
    • Patients
Patient perspectives on the good, the bad and the ugly of service design
  • We talk of innovation, but where do patients really see the opportunity for change?
    • Patients
    • Market Access
Educate payers on the value of your patient insights and their impact
  • How to articulate new patient journeys to make it straightforward for payers to model their long-term budgets
    • Patients
Personalised patient services as your key differentiator and performance enabler
  • Use more granular data to provide flexiblity and better value in your service provision for patients

Reimagine R&D with RWE

    • Medical Affairs
    • Data & RWE
    • Medical Affairs
    • Data & RWE
Modernise the development paradigm with RWE
  • Explore how Boehringer are using RWE to complement data from clinical trials with new levels of patient population understanding
  • Enhance development efforts with easily accessible and communicable RWD platforms
    • Medical Affairs
    • Data & RWE
Panel: Understand how to prove real-world effectiveness pre-launch
  • Case Study: Explore how phase II of the IMI GetReal programme is developing industry-wide standards and methodologies to accelerate adoption of RWE
  • Discuss how to incorporate RWE into the traditional R&D framework and tools available now to enhance operational efforts
    • Data & RWE
Case Study: FlatIron/Roche - the quest for regualtory grade RWE
  • Explore how Flatiron are advancing medical research, using technology to increase the credibility of EHRs
  • Discuss the implications “contemporary” control arms maybe have on traditional development processes

Reinvent your commercial strategy

    • Digital
    • Commercial
    • Digital
    • Commercial
Customer Experience: how to design an intentional customer journey that resonates at every step
  • Plan the journey and action you want your customers to take and find the moments that you can move the needle
    • Digital
    • Commercial
Achieve personalization through Omni-channel, longitudinal & behavioral analysis.
  • Establish an Omni-channel customer view, understand customer decision journeys
  • Observe customer behaviors and gather insights over short campaign iterations
    • Commercial
Sandoz Case Study: Commercial Excellence: as strong as the weakest link
  • Understand the end-to-end process and understand that customer centricity as the key lighthouse and everything you need to do to ensure you meet the expected customer experience.
    • Commercial
Dare to Dare: Redefine your customer approach and get ready for transformation
  • Change your perspective. Engage with patients as the key decision makers they’re becoming, and empower them to make educated decisions about their own health.
  • Go deep to understand the patient journey and core customer needs. Do it well, and the insights can reveal hidden value pools, and possibly force you to change your company strategy
    • Digital
    • Commercial
Panel: Streamlining of customer experience with an omnichannel approach
  • Advanced methods from consumer goods companies that cater to even fickle, disloyal consumer habits

RWE driven Market Access

    • Digital
    • Patients
    • Data & RWE
    • Market Access
    • Data & RWE
    • Market Access
Understand how RWE assessment fits into different HTA assessment methodologies across Europe
  • Bring it home: use local affiliates to feed into international RWE and access planning
  • Compare and contrast the range of HTA evidence hierarchies across Europe
    • Digital
    • Patients
    • Data & RWE
    • Market Access
Smarter use of PROs to turn patient value into payer value
  • How to move beyond clinical measures and successfully capture what truly matters to patients to secure access
    • Data & RWE
    • Market Access
Value-based contracting: use best-in-class predictive analytics
  • Forecast commercial performance by establishing value benchmarks and data quality from the outset

Session SubHeading

    • Keynotes
  • Wednesday 13th
  • 9.30-10.30am
    • Keynotes
    • Patient
Session title to go here written out like this

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

  • Identify the challenges pharma must overcome in this world of unpredictable social, economic and political change
  • Be the solution: redefine the role we play in the healthcare eco-system and come together to build the solutions that truly meet the need of patients and care givers
  • Recognise how other industries have been disrupted by unexpected competition and ensure pharma is prepared to face the challenges of tomorrow
  • Explore the world of healthcare from a higher perspective and ensure that we are at the core of the discussion on the shape of its future

Moderator: Steven Hildemann, SVP, Patient Safety and Chief Medical Officer, Merck Group

Ryan Olohan, Managing Director, Healthcare, Google

  • Wednesday 13th
  • 9.30-10.30am
    • Keynotes
    • Patient
Session title to go here written out like this

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

  • Identify the challenges pharma must overcome in this world of unpredictable social, economic and political change
  • Be the solution: redefine the role we play in the healthcare eco-system and come together to build the solutions that truly meet the need of patients and care givers
  • Recognise how other industries have been disrupted by unexpected competition and ensure pharma is prepared to face the challenges of tomorrow
  • Explore the world of healthcare from a higher perspective and ensure that we are at the core of the discussion on the shape of its future

Moderator: Steven Hildemann, SVP, Patient Safety and Chief Medical Officer, Merck Group

Ryan Olohan, Managing Director, Healthcare, Google

Session SubHeading

    • Keynotes
  • Wednesday 13th
  • 9.30-10.30am
    • Keynotes
    • Patient
Session title to go here written out like this

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

  • Identify the challenges pharma must overcome in this world of unpredictable social, economic and political change
  • Be the solution: redefine the role we play in the healthcare eco-system and come together to build the solutions that truly meet the need of patients and care givers
  • Recognise how other industries have been disrupted by unexpected competition and ensure pharma is prepared to face the challenges of tomorrow
  • Explore the world of healthcare from a higher perspective and ensure that we are at the core of the discussion on the shape of its future

Moderator: Steven Hildemann, SVP, Patient Safety and Chief Medical Officer, Merck Group

Ryan Olohan, Managing Director, Healthcare, Google

  • Wednesday 13th
  • 9.30-10.30am
    • Keynotes
    • Patient
Session title to go here written out like this

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

  • Identify the challenges pharma must overcome in this world of unpredictable social, economic and political change
  • Be the solution: redefine the role we play in the healthcare eco-system and come together to build the solutions that truly meet the need of patients and care givers
  • Recognise how other industries have been disrupted by unexpected competition and ensure pharma is prepared to face the challenges of tomorrow
  • Explore the world of healthcare from a higher perspective and ensure that we are at the core of the discussion on the shape of its future

Moderator: Steven Hildemann, SVP, Patient Safety and Chief Medical Officer, Merck Group

Ryan Olohan, Managing Director, Healthcare, Google

I want to attend I want the Brochure